Cliniboosta is an innovative platform dedicated to providing end-to-end services for Investigator-Initiated Trials (IIT) in China.We deeply integrate clinical research resources and facilitate accelerated parallel-track bridging for clinical trials between China and the US, UK, and Europe, fostering an efficient domestic IIT service ecosystem.We offer comprehensive support to pharmaceutical R&D companies, spanning from project initiation to data management.
By 2025, we have successfully assisted in the implementation of multiple IIT projects across various therapeutic areas, including oncology, rare diseases, autoimmunity, metabolic & chronic diseases, and neurodegenerative diseases. Acting as a core partner for global pharmaceutical companies advancing clinical innovation in China, Cliniboosta is committed to accelerating the translation of scientific research into clinical applications, ultimately benefiting patients both in China and abroad.
Deliver end-to-end IIT services in China, integrating clinical resources to accelerate the transformation of scientific achievements into clinical applications with compliance.
Drive global innovation in the field of IIT by leveraging technological empowerment, while bridging medical research and healthcare to accelerate medical breakthroughs.
